Karen Leigh Christman, Ph.D.

For MI survivors with moderate left ventricular (LV) dysfunction, an injectable biomaterial designed to mimic healthy extracellular matrix (ECM) was found to be safe in a phase I study.

Billed as a potential new approach to heart failure, VentriGel is an ECM hydrogel made from decellularized porcine myocardium and delivered by transendocardial injection using a catheter.

No adverse events definitely related to VentriGel were reported among 15 study subjects with LV dysfunction persisting at 60 days to 3 years post-MI and who had received percutaneous coronary intervention, according to Karen Christman, PhD, of the Sanford Consortium for Regenerative Medicine in La Jolla, California, and colleagues in their study published online in JACC: Basic to Translational Science… Continue reading.